Clinical trial tag: BRCA

 

An ovarian cancer researching looking into a microscope
Closed trial

Centurion: a trial looking at rucaparib with immunotherapy in relapsed ovarian cancer

The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

Closed trial

MOLTO: A trial looking at second course olaparib in BRCA positive recurrent ovarian cancer

Olaparib is a type of targeted treatment known as a PARP inhibitor. It blocks an enzyme called PARP, which helps damaged cancer cells to repair themselves. When PARP doesn't work the cancer cells won't be able to repair themselves and will die. Because of this, drugs such as olaparib are known to lengthen the amount of time between receiving chemot…

woman in laboratory
Closed trial

FORECEE: A study looking at female cancer risk prediction

The FORECEE (4C) research project is a new major study investigating the risk of breast, ovarian, womb and cervical cancer. Hormones are known to drive the development of particular diseases in women. Cervical cells are sensitive to the body’s own hormone levels in ways that are similar to the breast and other reproductive organs. This means tha…

A woman with ovarian cancer wearing a coat and green jumper walking down a hospital corridor
Closed trial

ARIEL 4: A study of rucaparib or chemotherapy in BRCA positive ovarian cancer

In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments. The drugs involved in this trial: Rucaparib – a targeted treatment known as a PARP inhibitor Paclitaxel – a sta…